Gilead Sciences, Inc.’s filing revealed that its Chief Medical Officer Parsey Merdad unloaded Company’s shares for reported $1.8 million on Sep 12 ’24. In the deal valued at $84.50 per share,21,246 shares were sold. As a result of this transaction, Parsey Merdad now holds 102,189 shares worth roughly $8.46 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Mercier Johanna sold 29,357 shares, generating $2,459,577 in total proceeds. Upon selling the shares at $83.78, the Chief Commercial Officer now owns 78,127 shares.
Before that, MERDAD V PARSEY bought 21,246 shares. Gilead Sciences, Inc. shares valued at $1,795,287 were divested by the Officer at a price of $84.50 per share.
Raymond James upgraded its Gilead Sciences, Inc. [GILD] rating to an Outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including Maxim Group’s analysts, who remained covering the stock and in early May has reiterated a ‘”a Buy”‘ rating for it. HSBC Securities also remained covering GILD and has increased its forecast on April 24, 2024 with a “Hold” recommendation from previously “Reduce” rating. Truist revised its rating on February 22, 2024. It rated GILD as “a Hold” which previously was an “a Buy”.
Price Performance Review of GILD
On Friday, Gilead Sciences, Inc. [NASDAQ:GILD] saw its stock fall -0.42% to $82.81. Over the last five days, the stock has gained 5.20%. Gilead Sciences, Inc. shares have risen nearly 2.22% since the year began. Nevertheless, the stocks have risen 7.11% over the past one year. While a 52-week high of $87.86 was reached on 01/19/24, a 52-week low of $62.07 was recorded on 05/31/24. SMA at 50 days reached $75.23, while 200 days put it at $73.41.
Levels Of Support And Resistance For GILD Stock
The 24-hour chart illustrates a support level at 81.86, which if violated will result in even more drops to 80.92. On the upside, there is a resistance level at 83.46. A further resistance level may holdings at 84.12. The Relative Strength Index (RSI) on the 14-day chart is 73.04, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.67, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 24.56%. Stochastics %K at 82.06% indicates the stock is a selling.
How much short interest is there in Gilead Sciences, Inc.?
A steep rise in short interest was recorded in Gilead Sciences, Inc. stocks on 2024-08-30, growing by 1.95 million shares to a total of 19.8 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-31 was 17.84 million shares. There was a rise of 9.86%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 09, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Hold”‘ rating along with a $75 price target.
